TON - August 2011 VOL 4, NO 5

TON - August 2011 VOL 4, NO 5 — August 24, 2011
CHICAGO—Exemestane appears to be a good alternative to tamoxifen for prevention of breast cancer in postmenopausal women, according to results of the randomized, placebo-controlled MAP.3 trial. Read More ›

TON - August 2011 VOL 4, NO 5 — August 24, 2011
Susan Beausang, President of 4Women.com and designer of the patented beaubeau head scarf, comes from 3 generations of breast cancer survivors. Hav - ing watched her grandmother, aunt, mother, and 2 of 4 sisters battle breast cancer, she and her siblings underwent genetic testing. Read More ›

TON - August 2011 VOL 4, NO 5 — August 24, 2011

CHICAGO—Oncology nurses know that nutrition interventions can help their patients, both during and after active treatment. But the evidence is scant, and personalizing it for each patient can be a challenge. To help, nutrition experts provided useful tips for nurses, along with a discussion of the evidence.

Read More ›

TON - August 2011 VOL 4, NO 5 — August 24, 2011
The hot, hazy days of summer are the perfect time for some of nature’s best produce. The tomato easily could be the unspoken mascot of the summer season. From July through September, make sure you take advantage of this delicious, nutrient-dense summer favorite. Read More ›

TON - August 2011 VOL 4, NO 5 — August 23, 2011

Maintaining a healthy body weight is important for all patients. But this is especially true for women with a breast cancer diagnosis, as an analysis of the California Teachers Study has shown a correlation between breast cancer deaths and body mass index (BMI).

Obesity (defined as BMI ≥30 kg/m²) increased a woman’s risk of dying of her breast cancer by 69%, compared with a woman with a BMI <25. For patients who were overweight at 18 years of age (defined as BMI 25-29), a similar increased risk in breast cancer mortality was detected.

Read More ›

TON - August 2011 VOL 4, NO 5 — August 23, 2011

Late-stage ovarian cancer patients responded well to an experimental carboplatin/decitabine combination therapy, even though they had become resistant to carboplatin, Indiana University researchers report. Furthermore, the researchers believe they have discovered biomarkers that could assist in identifying patients who are most likely to benefit from this therapy.

Read More ›

TON - August 2011 VOL 4, NO 5 — August 23, 2011

Increased awareness, earlier detection through screening, and advances in treatment have led to a decline in breast cancer death rates in the United States since 1990. Sadly, breast cancer continues to claim more women’s lives than any other cancer, besides lung cancer. For more statistical data on this prevalent disease, let’s take a look at breast cancer by the numbers.

About 1 in 8 (12%) women in the United States will develop invasive breast cancer over the course of her lifetime.

Read More ›

TON - August 2011 VOL 4, NO 5 — August 23, 2011

BOSTON—Treating patients with cancer who are morbidly obese presents unexpected challenges according to Vita Norton, RN, BSN, OCN, and Michelle Howard, RN, BSN, of Mass - achusetts General Hospital in Boston. Data indicate that obesity significantly increases the risk of endometrial and ovarian cancers and is associated with worse outcomes.

Read More ›

TON - August 2011 VOL 4, NO 5 — August 23, 2011

Case Presentation

Chief complaint: Generalized arthralgia for 5 months.

Read More ›

TON - August 2011 VOL 4, NO 5 — August 22, 2011

BOSTON—Recognizing steroid-induced hyperglycemia early and addressing it promptly can prevent significant ad - verse effects associated with this complication. Educating patients on the importance of and methods for maintaining good blood glucose control helps mitigate damage to the vascular system and kidneys from hyperglycemia. It also lessens susceptibility to infection, a complication of hyperglycemia that is of serious concern in immunocompromised patients. Read More ›


Page 2 of 3


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: